<DOC>
	<DOCNO>NCT01620138</DOCNO>
	<brief_summary>There available medical treatment option patient non-functioning pituitary adenoma ( NFPA ) resistant prolactinomas dopamine agonist ( DA ) cure surgery . The study receptor quantitative messenger ribonucleic acid ( mRNA ) expression level immunohistochemistry analysis might end good understanding tumor . Besides , assess vitro vivo response pasireotide ( NFPA prolactinomas ) cabergoline ( NFPA ) . These response compare receptor expression may tool predict element response compound .</brief_summary>
	<brief_title>Response Cabergoline Pasireotide Non-functioning Pituitary Adenomas Resistant Prolactinomas</brief_title>
	<detailed_description>The goal study : verify whether cabergoline pasireotide effective NFPA control tumor re-growth adjuvant therapy neurosurgery whether pasireotide capable normalize prolactin level patient prolactinomas resistant cabergoline ; ass mRNA level dopamine receptor type 2 ( DR2 ) SSTR1-5 protein expression ; evaluate vitro hormonal response cabergoline , octreotide pasireotide ; determine whether mRNA DR2/SSTR1-5 and/or protein expression and/or vitro hormonal response cabergoline , octreotide pasireotide correlate vivo response former last one . With data investigator intend establish mRNA analysis and/or protein expression NFPA resistant prolactinomas might predictive foretell factor concern drug treatment patient kind pituitary tumor also evaluate response vitro vivo treatment pasireotide NFPA resistant prolactinomas cabergoline NFPA .</detailed_description>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<mesh_term>Prolactinoma</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>Inclusion Criteria Male female patient age 18 year great Patients confirm diagnosis NFPA evidence : magnetic resonance imaging ( MRI ) confirmation pituitary adenoma No pituitary tumoral hormone hypersecretion Patients previous medical treatment Patients submit surgery cure . Lack cure define presence remnant tumor MRI least three month surgery ( without possible misinterpretation postsurgical change ) Patients confirm diagnosis resistant prolactinoma lack prolactin normalization tolerate cabergoline dosage 12 week Patients submit surgery due resistance cabergoline cure . Lack cure define lack serum prolactin normalization complete removal tumor load Patients sign informed consent Exclusion Criteria Previous pituitary radiotherapy High risk transsphenoidal surgery Patients symptomatic cholelithiasis Diabetic patient antidiabetic medication fast blood glucose poorly control evidence HbA1C &gt; 8 % Patients abnormal coagulation ( prothrombin time ( PT ) partial thromboplastin time ( PTT ) elevate 30 % normal limit ) ; Patients receive anticoagulant affect PT PTT Patients congestive heart failure ( NYHA Class III IV ) , unstable angina , sustain ventricular tachycardia , clinically significant bradycardia , advanced heart block , history acute MI le one year prior study entry clinically significant impairment cardiovascular function Patients risk factor torsade de pointes , i.e . patient baseline correct QT interval ( QTc ) &gt; 480 m , hypokalemia , family history long QT syndrome , concomitant medication know prolong QT interval Patients liver disease cirrhosis , chronic active hepatitis , chronic persistent hepatitis , patient ( alanine aminotransferase ) ALT/ ( aspartate aminotransferase ) AST 2 X upper limit normal ( ULN ) , serum creatinine &gt; 2.0 X ULN , serum bilirubin &gt; 2.0 X ULN , serum albumin &lt; 0.67 X low limit normal ( LLN ) Patients white blood cell ( WBC ) &lt; 3 X 109/L ; Hgb &lt; LLN ; Platelet count ( PLT ) &lt; 100 X 109/L Patients current prior medical condition interfere conduct study evaluation result opinion investigator Female patient pregnant lactating , childbearing potential practicing medically acceptable method birth control . Female patient must use barrier contraception condom . If oral contraception use , patient must practice method least two month prior enrollment must agree continue oral contraceptive throughout course study one month last dose study drug . Male patient sexually active require use condom study 1 month afterwards Patients history alcohol drug abuse 6 month period prior receive pasireotide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Non-functioning pituitary adenoma</keyword>
	<keyword>Prolactinomas</keyword>
	<keyword>Cabergoline</keyword>
	<keyword>Pasireotide</keyword>
	<keyword>somatostatin receptor</keyword>
	<keyword>Dopamine receptor</keyword>
</DOC>